Literature DB >> 6606691

Severe acquired immune deficiency syndrome in male homosexuals: diminished capacity to make interferon-alpha in vitro associated with severe opportunistic infections.

C Lopez, P A Fitzgerald, F P Siegal.   

Abstract

Natural killer cell function, directed against either K562 tumor targets or herpes simplex virus type 1-infected fibroblasts, was often low in patients with acquired immune deficiency syndrome (AIDS) but failed to distinguish these patients from either male homosexual controls or patients with lymphadenopathy. Mononuclear cells from patients with AIDS and opportunistic infections generated diminished levels of interferon-alpha in response to herpes simplex virus type 1-infected fibroblasts. This deficiency discriminated patients with severe opportunistic infections from most individuals with either generalized lymphadenopathy or Kaposi's sarcoma only and from male homosexual control subjects. The deficiency in interferon-alpha generation may be the consequence of the opportunistic infections that these individuals have contracted or may be a direct manifestation of AIDS itself.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6606691     DOI: 10.1093/infdis/148.6.962

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  34 in total

Review 1.  Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history.

Authors:  Patricia Fitzgerald-Bocarsly; Jihong Dai; Sukhwinder Singh
Journal:  Cytokine Growth Factor Rev       Date:  2008-01-11       Impact factor: 7.638

2.  Natural killer cells in intravenous drug abusers with lymphadenopathy syndrome.

Authors:  G Poli; M Introna; F Zanaboni; G Peri; M Carbonari; F Aiuti; A Lazzarin; M Moroni; A Mantovani
Journal:  Clin Exp Immunol       Date:  1985-10       Impact factor: 4.330

3.  Circulating dendritic cells and interferon-alpha production in patients with tuberculosis: correlation with clinical outcome and treatment response.

Authors:  M Lichtner; R Rossi; F Mengoni; S Vignoli; B Colacchia; A P Massetti; I Kamga; A Hosmalin; V Vullo; C M Mastroianni
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

4.  Association of alpha interferon production with natural killer cell lysis of U937 cells infected with human immunodeficiency virus.

Authors:  G Rappocciolo; J F Toso; D J Torpey; P Gupta; C R Rinaldo
Journal:  J Clin Microbiol       Date:  1989-01       Impact factor: 5.948

5.  Reversal of human immunodeficiency virus type 1 protein-induced inhibition of natural killer cell activity by alpha interferon and interleukin-2.

Authors:  M P Nair; S A Schwartz
Journal:  Clin Diagn Lab Immunol       Date:  2000-01

6.  PolyI.polyC12U-mediated inhibition of loss of alloantigen responsiveness viral replication in human CD4+ T cell clones exposed to human immunodeficiency virus in vitro.

Authors:  J Laurence; J Kulkosky; S M Friedman; D N Posnett; P O Ts'o
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

Review 7.  The tug-of-war between dendritic cells and human chronic viruses.

Authors:  Saifur Rahman; Zafar K Khan; Pooja Jain
Journal:  Int Rev Immunol       Date:  2011 Oct-Dec       Impact factor: 5.311

Review 8.  Interferon-alpha in malignant and viral diseases. A review.

Authors:  R T Dorr
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

9.  Plasmacytoid dendritic cell dynamics and alpha interferon production during Simian immunodeficiency virus infection with a nonpathogenic outcome.

Authors:  Ousmane M Diop; Mickaël J-Y Ploquin; Lorenzo Mortara; Abdourahmane Faye; Béatrice Jacquelin; Désirée Kunkel; Pierre Lebon; Cécile Butor; Anne Hosmalin; Françoise Barré-Sinoussi; Michaela C Müller-Trutwin
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

10.  Selective decrease in human immunodeficiency virus type 1 (HIV-1)-induced alpha interferon production by peripheral blood mononuclear cells during HIV-1 infection.

Authors:  J Ferbas; J Navratil; A Logar; C Rinaldo
Journal:  Clin Diagn Lab Immunol       Date:  1995-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.